Phacilitate Leaders World

Sponsors & Exhibitors

Aseptic Technologies

ASEPTIC TECHNOLOGIES develops, manufactures and markets innovative aseptic solution for the BioPharmaceutical industry.

Its equipment and devices are designed to provide safer & easier operations for aseptic fill and finish, the best-known being the AT-Closed Vial® technology.

The AT-Closed Vial® is manufactured in ISO 5 clean room with the stopper secured in place and gamma sterilized. Vial size ranges from 1 to 50ml.

The filling of these ready-to-use vials is performed by a special needle piercing the stopper and dispensing the drug product. The stopper is then immediately resealed by a laser and a cap is snap-fitted on it.

Various equipment offer an easy scale-up from manual to fully automated operation.

The benefits of the technology are: better sterility assurance, reduced investments, increased safety during whole supply chain, strong operating cost reduction.

The AT-Closed Vial® technology is widely used in the Cell and Gene Therapies as it offers uncompromised container closure integrity even during storage at cryogenic temperature.

Visit Website
View all Sponsors & Exhibitors
Loading
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK